Systems biology of vaccination for seasonal influenza in humans
- PMID: 21743478
- PMCID: PMC3140559
- DOI: 10.1038/ni.2067
Systems biology of vaccination for seasonal influenza in humans
Abstract
Here we have used a systems biology approach to study innate and adaptive responses to vaccination against influenza in humans during three consecutive influenza seasons. We studied healthy adults vaccinated with trivalent inactivated influenza vaccine (TIV) or live attenuated influenza vaccine (LAIV). TIV induced higher antibody titers and more plasmablasts than LAIV did. In subjects vaccinated with TIV, early molecular signatures correlated with and could be used to accurately predict later antibody titers in two independent trials. Notably, expression of the kinase CaMKIV at day 3 was inversely correlated with later antibody titers. Vaccination of CaMKIV-deficient mice with TIV induced enhanced antigen-specific antibody titers, which demonstrated an unappreciated role for CaMKIV in the regulation of antibody responses. Thus, systems approaches can be used to predict immunogenicity and provide new mechanistic insights about vaccines.
Conflict of interest statement
The authors declare no competing financial interests.
Figures
![Figure 1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/3140559/bin/nihms301940f1.gif)
![Figure 2](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/3140559/bin/nihms301940f2.gif)
![Figure 3](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/3140559/bin/nihms301940f3.gif)
![Figure 4](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/3140559/bin/nihms301940f4.gif)
![Figure 5](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/3140559/bin/nihms301940f5.gif)
![Figure 6](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/3140559/bin/nihms301940f6.gif)
Comment in
-
Solving vaccine mysteries: a systems biology perspective.Nat Immunol. 2011 Jul 19;12(8):729-31. doi: 10.1038/ni.2078. Nat Immunol. 2011. PMID: 21772284 No abstract available.
Similar articles
-
Inactivated influenza virus vaccines: the future of TIV and QIV.Curr Opin Virol. 2017 Apr;23:102-106. doi: 10.1016/j.coviro.2017.04.005. Epub 2017 May 12. Curr Opin Virol. 2017. PMID: 28505524 Free PMC article. Review.
-
Differences in antibody responses between trivalent inactivated influenza vaccine and live attenuated influenza vaccine correlate with the kinetics and magnitude of interferon signaling in children.J Infect Dis. 2014 Jul 15;210(2):224-33. doi: 10.1093/infdis/jiu079. Epub 2014 Feb 4. J Infect Dis. 2014. PMID: 24495909 Free PMC article.
-
Safety and immunogenicity of live attenuated and inactivated influenza vaccines in children with cancer.J Infect Dis. 2011 Nov 15;204(10):1475-82. doi: 10.1093/infdis/jir561. Epub 2011 Sep 23. J Infect Dis. 2011. PMID: 21949042 Clinical Trial.
-
Live and inactivated influenza vaccines induce similar humoral responses, but only live vaccines induce diverse T-cell responses in young children.J Infect Dis. 2011 Sep 15;204(6):845-53. doi: 10.1093/infdis/jir436. Epub 2011 Aug 15. J Infect Dis. 2011. PMID: 21846636 Free PMC article.
-
The relative efficacy of trivalent live attenuated and inactivated influenza vaccines in children and adults.Influenza Other Respir Viruses. 2011 Mar;5(2):67-75. doi: 10.1111/j.1750-2659.2010.00183.x. Epub 2010 Nov 19. Influenza Other Respir Viruses. 2011. PMID: 21306569 Free PMC article. Review.
Cited by
-
Pre-vaccination transcriptomic profiles of immune responders to the MUC1 peptide vaccine for colon cancer prevention.medRxiv [Preprint]. 2024 May 10:2024.05.09.24305336. doi: 10.1101/2024.05.09.24305336. medRxiv. 2024. PMID: 38766010 Free PMC article. Preprint.
-
Electron transport chain capacity expands yellow fever vaccine immunogenicity.EMBO Mol Med. 2024 Jun;16(6):1310-1323. doi: 10.1038/s44321-024-00065-7. Epub 2024 May 14. EMBO Mol Med. 2024. PMID: 38745062 Free PMC article.
-
Multiparameter Flow Cytometry Monitoring of T Cell Responses.Methods Mol Biol. 2024;2807:325-342. doi: 10.1007/978-1-0716-3862-0_22. Methods Mol Biol. 2024. PMID: 38743238
-
Integrated longitudinal multiomics study identifies immune programs associated with acute COVID-19 severity and mortality.J Clin Invest. 2024 May 1;134(9):e176640. doi: 10.1172/JCI176640. J Clin Invest. 2024. PMID: 38690733 Free PMC article. Clinical Trial.
-
Vaccines Induce Homeostatic Immunity, Generating Several Secondary Benefits.Vaccines (Basel). 2024 Apr 9;12(4):396. doi: 10.3390/vaccines12040396. Vaccines (Basel). 2024. PMID: 38675778 Free PMC article. Review.
References
-
- Fiore AE, et al. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Recomm Rep. 2010;59:1–62. - PubMed
-
- Zeman AM, et al. Humoral and cellular immune responses in children given annual immunization with trivalent inactivated influenza vaccine. Pediatr Infect Dis J. 2007;26:107–115. - PubMed
Publication types
MeSH terms
Substances
Associated data
- Actions
Grants and funding
- N01AI50025/AI/NIAID NIH HHS/United States
- U19AI090023/AI/NIAID NIH HHS/United States
- R01DK057665/DK/NIDDK NIH HHS/United States
- U19 AI057266-08/AI/NIAID NIH HHS/United States
- R01 DK057665-13/DK/NIDDK NIH HHS/United States
- U54AI057157/AI/NIAID NIH HHS/United States
- N01AI30048/AI/NIAID NIH HHS/United States
- U19 AI057266-09/AI/NIAID NIH HHS/United States
- UL1 TR000454/TR/NCATS NIH HHS/United States
- R01 GM033976/GM/NIGMS NIH HHS/United States
- R37 AI048638-11/AI/NIAID NIH HHS/United States
- R37AI48638/AI/NIAID NIH HHS/United States
- UL1 RR025008/RR/NCRR NIH HHS/United States
- U19 AI090023-02/AI/NIAID NIH HHS/United States
- AI057266/AI/NIAID NIH HHS/United States
- R37 AI048638/AI/NIAID NIH HHS/United States
- HHSN266200700006C/AI/NIAID NIH HHS/United States
- R38 AI140299/AI/NIAID NIH HHS/United States
- R01 DK057665-12/DK/NIDDK NIH HHS/United States
- U19 AI090023/AI/NIAID NIH HHS/United States
- R01 DK074701/DK/NIDDK NIH HHS/United States
- U19 AI057266/AI/NIAID NIH HHS/United States
- U19 AI090023-01/AI/NIAID NIH HHS/United States
- R01 DK057665/DK/NIDDK NIH HHS/United States
- U19AI057266/AI/NIAID NIH HHS/United States
- R37 DK057665/DK/NIDDK NIH HHS/United States
- R37 AI048638-12/AI/NIAID NIH HHS/United States
- AI30048/AI/NIAID NIH HHS/United States
- DK074701/DK/NIDDK NIH HHS/United States
- N01 AI50025/AI/NIAID NIH HHS/United States
- U54 AI057157/AI/NIAID NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical